Clinical trials · North Carolina
Hematopoietic Stem Cell Transplant clinical trials in North Carolina
We’re tracking 17 recruiting hematopoietic stem cell transplant studies with a site in North Carolina — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Chapel Hill, North CarolinaAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Asheville, North CarolinaAges Up to 30 years - NCT06328127Recruiting
Positive psychology program for stem cell transplant survivors
This study tests a positive psychology program—simple exercises to help you feel better emotionally—for people who are about 3 months past a donor stem cell transplant. It's done over the phone, so you can join from home.
Durham, North CarolinaAges 18 years+ - NCT06802406Recruiting
Nutrition support for transplant or cell therapy patients
This study tests a program to help patients who are getting a transplant or cell therapy and have trouble getting enough food. It provides nutrition resources to improve their health during treatment.
Durham, North CarolinaAges 8–80 - NCT06575712Recruiting
Coping skills training to manage symptoms and daily steps
This study tests a coping skills training program to help people who have had a stem cell transplant or CAR-T cell therapy for blood cancer manage fatigue, pain, and stress. It may help you feel better and be more active in daily life.
Durham, North CarolinaAges 18–99 - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Chapel Hill, North CarolinaAges 18 years+ - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Asheville, North CarolinaAges 12 months–30 years - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Chapel Hill, North CarolinaAges Any age - NCT03667599Recruiting
Home care program after your stem cell transplant
This study tests whether extra home-based medical support after a stem cell transplant can help patients during recovery. If you’re eligible, a trained care team will support you at home so you’re safer and better managed after discharge.
Durham, North CarolinaAges 18–80 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Durham, North CarolinaAges 18–55 - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Asheville, North CarolinaAges Up to 21 years - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Huntersville, North CarolinaAges 18 years+ - NCT06724237RecruitingPhase 3
High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Chapel Hill, North CarolinaAges 18–75 - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Chapel Hill, North CarolinaAges 18–66 - NCT06941389Recruiting
Comparing stem cell transplant vs standard therapy for sickle cell disease
This study compares two treatment approaches for children with sickle cell anemia: a stem cell transplant from a matched family donor versus continuing regular disease-modifying medicines. It aims to see which treatment works better over time.
Charlotte, North CarolinaAges 3–20 - NCT01890486Recruiting
Collecting information from people having a stem cell transplant
This study aims to collect, store, and share data from patients who are receiving standard intensive treatment and a stem cell transplant from either their own cells or a donor. It may help improve how future patients are treated by building a reliable record of outcomes and care patterns.
Winston-Salem, North CarolinaAges 18–120 - NCT03509961RecruitingPhase 2
Reducing total body radiation for children with leukemia transplants
This study looks at whether some children and young adults with B-ALL can safely get a transplant without total body irradiation (TBI), based on special leukemia test results. It’s meant to help lower radiation-related risks while keeping leukemia control strong.
Charlotte, North CarolinaAges 1–25
Hematopoietic Stem Cell Transplant trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting hematopoietic stem cell transplant studies listed above.
- Duke University Medical Center · 8 studies
- UNC Lineberger Comprehensive Cancer Center · 7 studies
- Carolinas Medical Center/Levine Cancer Institute · 6 studies
- Novant Health Presbyterian Medical Center · 5 studies
- Wake Forest University Health Sciences · 5 studies
- East Carolina University · 4 studies
- Duke Cancer Institute · 3 studies
- Mission Hospital · 3 studies
What taking part in a hematopoietic stem cell transplant study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Hematopoietic Stem Cell Transplant trials in other states
Common questions
- Are there hematopoietic stem cell transplant clinical trials in North Carolina?
- Yes. We're currently tracking 17 recruiting hematopoietic stem cell transplant studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hematopoietic stem cell transplant study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hematopoietic stem cell transplant trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hematopoietic stem cell transplant studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.